Holen Sie sich die Stockscreener-App
59.43
6.33%
3.54
Handel nachbörslich:
59.43
Schlusskurs vom Vortag:
$55.89
Offen:
$54.34
24-Stunden-Volumen:
3.55M
Relative Volume:
2.20
Marktkapitalisierung:
$11.34B
Einnahmen:
$2.75B
Nettoeinkommen (Verlust:
$322.29M
KGV:
35.59
EPS:
1.67
Netto-Cashflow:
$300.88M
1W Leistung:
-13.01%
1M Leistung:
-17.72%
6M Leistung:
-14.86%
1J Leistung:
-33.21%
1-Tages-Spanne:
$52.93
$59.88
1-Wochen-Bereich:
$52.93
$68.54
52-Wochen-Spanne:
$52.93
$94.85
Biomarin Pharmaceutical Inc Stock (BMRN) Company Profile
Firmenname
Biomarin Pharmaceutical Inc
Sektor
Branche
Telefon
(415) 506-6700
Adresse
105 DIGITAL DRIVE, NOVATO, CA
Vergleichen Sie BMRN mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
BMRN
Biomarin Pharmaceutical Inc
|
59.43 | 11.34B | 2.75B | 322.29M | 300.88M | 1.67 |
|
VRTX
Vertex Pharmaceuticals Inc
|
482.30 | 123.99B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
576.72 | 63.05B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
564.13 | 34.41B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
243.27 | 31.49B | 2.25B | -278.16M | -42.59M | -2.17 |
|
BNTX
Biontech Se Adr
|
94.14 | 22.63B | 3.30B | -501.07M | 1.03B | -2.1146 |
Biomarin Pharmaceutical Inc Stock (BMRN) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-02-24 | Hochstufung | Oppenheimer | Perform → Outperform |
| 2024-11-15 | Eingeleitet | Wolfe Research | Outperform |
| 2024-10-30 | Herabstufung | William Blair | Outperform → Mkt Perform |
| 2024-10-10 | Fortgesetzt | Raymond James | Outperform |
| 2024-08-20 | Hochstufung | Bernstein | Mkt Perform → Outperform |
| 2024-05-17 | Herabstufung | Robert W. Baird | Outperform → Neutral |
| 2024-05-14 | Eingeleitet | Evercore ISI | Outperform |
| 2023-11-15 | Eingeleitet | Wells Fargo | Overweight |
| 2023-10-23 | Hochstufung | Bernstein | Underperform → Mkt Perform |
| 2023-09-28 | Eingeleitet | Raymond James | Mkt Perform |
| 2023-09-18 | Eingeleitet | UBS | Buy |
| 2023-07-27 | Eingeleitet | Scotiabank | Sector Perform |
| 2023-07-05 | Hochstufung | BMO Capital Markets | Market Perform → Outperform |
| 2023-06-14 | Fortgesetzt | Credit Suisse | Outperform |
| 2023-03-21 | Eingeleitet | Bernstein | Underperform |
| 2023-02-22 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2023-02-21 | Eingeleitet | Citigroup | Neutral |
| 2023-01-30 | Eingeleitet | BMO Capital Markets | Market Perform |
| 2023-01-18 | Eingeleitet | Canaccord Genuity | Hold |
| 2022-10-31 | Hochstufung | Oppenheimer | Perform → Outperform |
| 2022-07-13 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2022-06-13 | Fortgesetzt | Wedbush | Neutral |
| 2022-04-25 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2021-11-22 | Hochstufung | William Blair | Mkt Perform → Outperform |
| 2021-10-07 | Fortgesetzt | Jefferies | Buy |
| 2021-09-09 | Hochstufung | Stifel | Hold → Buy |
| 2021-06-04 | Fortgesetzt | Robert W. Baird | Outperform |
| 2021-04-26 | Fortgesetzt | Credit Suisse | Outperform |
| 2021-03-04 | Fortgesetzt | Guggenheim | Buy |
| 2021-03-01 | Hochstufung | Evercore ISI | In-line → Outperform |
| 2020-08-20 | Herabstufung | Citigroup | Buy → Neutral |
| 2020-08-20 | Herabstufung | William Blair | Outperform → Mkt Perform |
| 2020-08-19 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2020-08-19 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2020-08-19 | Herabstufung | Stifel | Buy → Hold |
| 2020-07-08 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2020-07-06 | Bestätigt | Citigroup | Buy |
| 2020-01-28 | Eingeleitet | BMO Capital Markets | Market Perform |
| 2020-01-27 | Eingeleitet | BMO Capital Markets | Market Perform |
| 2020-01-24 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
| 2019-11-27 | Hochstufung | Barclays | Equal Weight → Overweight |
| 2019-11-12 | Eingeleitet | SunTrust | Buy |
| 2019-10-17 | Fortgesetzt | BofA/Merrill | Buy |
| 2019-05-23 | Fortgesetzt | Citigroup | Buy |
| 2019-04-09 | Fortgesetzt | Raymond James | Outperform |
| 2019-01-02 | Herabstufung | Raymond James | Outperform → Mkt Perform |
| 2018-12-14 | Eingeleitet | Wolfe Research | Outperform |
| 2018-10-01 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2018-08-07 | Bestätigt | Stifel | Buy |
| 2018-08-03 | Bestätigt | Stifel | Buy |
Alle ansehen
Biomarin Pharmaceutical Inc Aktie (BMRN) Neueste Nachrichten
Will Trump Tariffs Make or Break Healthcare Space? 3 Stocks to Rely On - TradingView
5 Biotech Stocks Worth Adding Amid Global Uncertainty in 2025 - TradingView
What Makes BioMarin (BMRN) a New Buy Stock - Yahoo Finance
BMRN vs. CSLLY: Which Stock Is the Better Value Option? - Yahoo Finance
Are You a Value Investor? This 1 Stock Could Be the Perfect Pick - Yahoo Finance
BMRN stock touches 52-week low at $60.63 amid market shifts - Investing.com Canada
BMRN's PKU Drug Palynziq Meets Goal in Late-Stage Pediatric Study - MSN
BioMarin succeeds in trial for its metabolic disorder treatment - MSN
BMRN stock touches 52-week low at $60.63 amid market shifts By Investing.com - Investing.com South Africa
Edmond DE Rothschild Holding S.A. Boosts Stake in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) - MarketBeat
BioMarin Pharmaceutical: Pegasus Success May Lead To Palynziq Label Expansion (BMRN) - Seeking Alpha
Nomura Asset Management Co. Ltd. Sells 73,310 Shares of BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) - MarketBeat
BioMarin’s trial for phenylketonuria therapy meets primary efficacy endpoint - Yahoo Finance
The Top 12 Companies Hiring in Biopharma Now - BioSpace
BioMarin (BMRN) Advances PALYNZIQ in Key Late-Stage Trial for PK - GuruFocus
BioMarin’s PALYNZIQ shows promise for adolescents with PKU - Investing.com India
BioMarin’s PALYNZIQ shows promise for adolescents with PKU By Investing.com - Investing.com South Africa
BioMarin Seeks Label Expansion For Palynziq After Positive Phase 3 Results In Adolescent Patients - Benzinga
BioMarin's Trial for Phenylketonuria Shows Palynziq Reduces Blood Phenylalanine in Adolescents - MarketScreener
Is BioMarin Pharmaceutical Inc. (BMRN) The Most Profitable Biotech Stock To Buy Right Now? - Insider Monkey
Is Royalty Pharma plc (RPRX) The Most Profitable Biotech Stock To Buy Right Now? - Yahoo Finance
Here's Why BioMarin Pharmaceutical (BMRN) is a Strong Growth Stock - Yahoo Finance
BioMarin (BMRN) Beats on Q1 Earnings, Voxzogo Drives Sales - MSN
Breakthrough: PALYNZIQ Shows Powerful Results in Teen PKU Patients, Opening New Market - Stock Titan
BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Shares Sold by Mitsubishi UFJ Trust & Banking Corp - MarketBeat
The Price Is Right For BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) - simplywall.st
11 Best Gene Therapy Stocks to Buy According to Analysts - Insider Monkey
US FDA approves Sanofi's bleeding disorder therapy - MarketScreener
Here's Why BioMarin Pharmaceutical (BMRN) is a Strong Momentum Stock - Yahoo Finance
Is BioMarin Pharmaceutical Inc. (BMRN) a Promising Biotech Stock According to Wall Street Analysts - Insider Monkey
BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Holdings Lifted by Sector Gamma AS - MarketBeat
Insider Sell Alert: Erin Burkhart Sells Shares of Biomarin Pharm - GuruFocus
BioMarin (BMRN) Up 4.2% Since Last Earnings Report: Can It Continue? - Yahoo Finance
Here's Why BioMarin Pharmaceutical (BMRN) is a Strong Value Stock - Yahoo Finance
Q4 Earnings Review: Therapeutics Stocks Led by BioMarin Pharmaceutical (NASDAQ:BMRN) - Yahoo Finance
BioMarin pharmaceutical CAO Erin Burkhart sells $92,618 in stock By Investing.com - Investing.com Australia
BioMarin pharmaceutical CAO Erin Burkhart sells $92,618 in stock - Investing.com India
Citi maintains Neutral on BioMarin stock, price target at $82 - Investing.com
BioMarin Pharmaceutical (BMRN): Among Paul Singer’s Latest Portfolio’s Top Stock Picks - Insider Monkey
BioMarin Presents New Data Demonstrating Favorable Safety and Strong Adherence in Real-World Clinical Practice with VOXZOGO® (vosoritide) in Children Under 3 with Achondroplasia at 2025 American College of Medical Genetics and Genomics (ACMG) - PR Newswire
BioMarin's VOXZOGO Achieves Breakthrough Safety Milestone in Toddlers with Dwarfism - Stock Titan
BMRN vs. CSLLY: Which Stock Should Value Investors Buy Now? - Yahoo Finance
Is BioMarin Pharmaceutical (BMRN) the Best Biotech Stock According to Billionaires? - Yahoo Finance
15 Best Biotech Stocks to Buy According to Billionaires - Insider Monkey
Is BioMarin (BMRN) a Solid Growth Stock? 3 Reasons to Think "Yes" - Yahoo Finance
SpringWorks Shares Rise More Than 30% in 3 Months: Here's Why - TradingView
Wall Street Analysts Believe BioMarin (BMRN) Could Rally 36.57%: Here's is How to Trade - Yahoo Finance
Why BioMarin Pharmaceutical (BMRN) is a Top Momentum Stock for the Long-Term - Yahoo Finance
Finanzdaten der Biomarin Pharmaceutical Inc-Aktie (BMRN)
Umsatz
Nettogewinn
Free Cashflow
ENV
4.73%
1.48%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):